Molecular and Cellular Characterization of MALT Lymphoma
ConditionMALT Lymphoma
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorInternational Extranodal Lymphoma Study Group (IELSG)
About this trial
Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) is an slow growing malignancy characterized by marked biological and clinical differences across different anatomical sites.
Using participants' samples and clinical information, this observational and non-interventional research aims to generate a comprehensive molecular and cellular atlas of MALT lymphoma. The results will enable the identification of biologically meaningful tumor subtypes, microenvironmental niches, and candidate biomarkers with potential relevance for the diagnosis, prognosis, and therapy of MALT lymphoma.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Male or female adults 18 years or older
Diagnosis of extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue on histology after Jan 1st, 2000.
Availability of tumor material from biopsies (either frozen or formalin-fixed paraffin-embedded) (FFPE).
Availability of the baseline and follow-up annotations.
Disqualifiers
None
Trial population
Adult patients with diagnosis of extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue on histology after Jan 1st, 2000
Trial design
Design model
Cohort
Time perspective
Retrospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
Molecular and spatial profiles of MALT lymphoma
Generation of high-resolution molecular and spatial profiles of MALT lymphoma tissues, including annotation of malignant and non-malignant cell populations.
Time frame
6 months: from the end of samples collection to the end of study analysisSecondary outcomes
1
Creation of a curated multi-omics dataset
Identification of spatial tumor-immune interactions, characterization of BCR/TCR clonality, derivation of molecular signatures associated with anatomical site and microenvironment, and creation of a curated multi-omics dataset suitable for deposition in controlled-access repositories
Time frame
6 months: from the end of samples collection to the end of study analysis2
Extraction of clinically relevant features using artificial intelligence (AI) from histology sections
Time frame
6 months: from the end of samples collection to the end of study analysisSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: